EBS EBS エマ―ジェント・バイオソリュ―ションズ

 EBSのチャート


 EBSの企業情報

symbol EBS
会社名 Emergent BioSolutions Inc (EBS エマ―ジェント・バイオソリュ―ションズ)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 事業概要 エマージェント・バイオソリューションズ(Emergent BioSolutions Inc.)は生命科学会社である。同社は偶発的かつ自然発生的な公衆衛生上の脅威に対処する専門製品を民間人および軍人へ提供することを通じて生命健康の保護と強化に集中する。同社は公衆衛生脅威(PHTs)に対処する医療対策の開発、製造、商業化の集中する。PHTsは化学、生物、放射線、核及び爆発的な脅威と新たな感染症、2つのカテゴリで展開する。同社はワクチンと抗感染薬、抗体療法、デバイスと契約製造、四つのビジネスユニットで事業を展開する。ワクチンと抗感染薬ユニット炭疽病の一般的な予防および曝露後の予防用のBioThraxを含む。デバイスビジネスユニットは反応性皮膚除染ローションキット(RSDL)とトロビガード(硫酸アトロピン、塩化オビドキシム)などの市販されている製品を含む。  エマ―ジェント・バイオソリュ―ションズは米国の製薬メ―カ―。医療ニ―ズと新興の健康への脅威に対処する製品を開発、製造。感染症の炭疽菌などバイオテロや生物戦の可能性のある薬剤対策の開発・供給を政府支援で行う。市販されている主な製品は「BioThrax」。その他、慢性リンパ球性白血病など腫瘍学対象の臨床を展開中。  Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.
本社所在地 400 Professional Drive Suite 400 Gaithersburg MD 20879 USA
代表者氏名 Fuad El-Hibri
代表者役職名 Executive Chairman of the Board
電話番号 +1 240-631-3200
設立年月日 35916
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 1705人
url www.emergentbiosolutions.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) 152.00000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 2586.62400
売上高 売上高(百万ドル) 782.40000
企業価値(EV) 企業価値(EV)(百万ドル) 3269.02400
当期純利益 当期純利益(百万ドル) 58.40000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Emergent Biosolutions Inc revenues increased 39% to $782.4M. Net income before extraordinary items decreased 29% to $58.4M. Revenues reflect Product sales increase of 44% to $606.5M Contract manufacturing increase of 43% to $98.9M Contracts and grants increase of 9% to $77M. Net income was offset by Research and Development increase of 47% to $142.8M (expense).

 EBSのテクニカル分析


 EBSのニュース

   Global Toxoid Vaccines Market Growing By Increasing Market Share And Forecast 2027 With Top Key Players-GlaxoSmithKline plc, Grifols, S.A, Zoetis Services LLC., Virbac. Sanofi, Merck & Co., Inc., Emergent BioSolutions Inc, Integrated BioTherapeutics  2020/11/12 14:05:26 OpenPR
The Toxoid Vaccines report published by Data Bridge Market research is the representation of data and analysis of the market. It gives detailed analysis of the current market scenario and a market forecast till 2027. The data included
   Global Polio Vaccine Market 2025 Trends Forecast Analysis by Manufacturers: Merck, Johnson&Johnson, Emergent BioSolutions, GlaxoSmithKline, CSL Limited & more  2020/11/06 12:12:48 OpenPR
According to Market Growth Insight, the Polio Vaccine Market is anticipated to reach USD XX billion by the end of 2026 with projected CAGR of XX% over the near future. The report delivers thorough analysis of the key drivers, opportunities,
   Mitiska REIM announces an EUR 33 million financing facility for its four newest Romanian retail parks with Erste Group Bank AG - Business Review  2020/11/02 14:27:02 Business Review
Mitiska REIM, the leading specialist investor in European retail parks and convenience centres, has today announced it has secured an EUR 33 million
   Ausblick: Erste Group Bank öffnet die Bücher zum abgelaufenen Quartal  2020/11/01 13:07:00 Finanzen AT
Erste Group Bank veröffentlicht am 02.11.2020 auf der all-dreimonatlichen Finanzkonferenz die Zahlen zum am 30.09.2020 abgelaufenen Jahresviertel.Der Gewinn je Aktie dürfte sich laut 5 Analysten für das vergangene Quartal auf durchschnittlich 0,673 EUR je Aktie belaufen. Im Vorjahresviertel hatte
   Plasma Fractionation Market Top Key Players- Emergent BioSolutions (US), Intas Biopharmaceuticals (India), Bharat Serums and Vaccines Limited (India), SK Plasma (Republic of Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US)G  2020/10/27 11:43:02 OpenPR
Summary of the Plasma Fractionation Market Report Due to the various economic, technological, research & development and geographical aspects, the Plasma Fractionation Market would gain a healthy CAGR and market size from 2020 to 2027. The growth trend would
   Late-stage study of Emergent Bio's COVID-19 plasma-derived therapy launched (NYSE:EBS)  2020/10/08 20:41:56 Seeking Alpha
Emergent BioSolutions (NYSE:EBS) announces the initiation of an NIAID-sponsored Phase 3 clinical trial, INSIGHT-013, evaluating COVID-HIG (one of four such
   Shigellosis Gastroenteritis Treatment Market Outlook 2020-In-Depth Insight Of Sales Analysis, Growth Forecast And Upcoming Trends 2026 || Emergent BioSolutions Inc, Pfizer Inc, LimmaTech Biologics AG, GlaxoSmithKline plc, Zydus Cadila, Bionpharma  2020/10/07 14:57:26 OpenPR
Data Bridge Market Research has added an exhaustive research study of the Shigellosis Gastroenteritis Treatment Market driver and intricately analyzing the business vertical. The research report has abilities to raise as the most significant market worldwide as it has remained
   Live Attenuated Vaccines Market Size and Growth to 2026: Sanofi, Emergent BioSolutions Inc, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, AstraZeneca  2020/10/06 12:05:22 OpenPR
Global live attenuated vaccines market is expected to grow at a growing CAGR in the forecast period of 2019-2026. Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling
   Vaccine Market Professional Survey Report: Merck Co., Inc, Sanofi, CSL Limited, Panacea Biotec Ltd., Novavax, Emergent BioSolutions Inc, Inovio Pharmaceuticals, Inc  2020/09/30 19:15:01 OpenPR
Vaccine Market By Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Others), Type (Monovalent Vaccines, Multivalent Vaccines), Indication (Pneumococcal Disease, Influenza, Meningococcal Disease, Polio, Rotavirus, Hepatitis, Dengue, Herpes Zoster, Others), Route of Administration (Oral, Parenteral), By End Users (Hospitals,
   Here Is Everything We Know About A COVID-19 Vaccine  2020/09/04 09:30:00 Zero Hedge
Here Is Everything We Know About A COVID-19 Vaccine Tyler Durden Fri, 09/04/2020 - 05:30 Under normal conditions, vaccines require as long as ten years of testing before they're approved by regulators, then it takes some more time for drug companies to produce and distribute the product to millions of patients around the world. Until very recently, the notion that the world could quickly develop and mass produce a vaccine for some new infectious disease within a matter of months seemed impossible. Of course, these aren't normal times. After unveiling the adenovirus-vector vaccine developed by the Gameleya Institute, Russian President Putin claimed that the vaccine was tested first on a small group of willing participants, including one of his own adult daughters. The implication was that traditional standards of medical ethics don't always apply during extreme situations. With vaccine news being the dominant story on Thursday , as investors around the world watched as the administration pushed the states to prepare to start distributing vaccine doses on an emergency basis come Nov. 1.
   Shigellosis Gastroenteritis Treatment Market Outlook 2020-In-Depth Insight Of Sales Analysis, Growth Forecast And Upcoming Trends 2026 || Emergent BioSolutions Inc, Pfizer Inc, LimmaTech Biologics AG, GlaxoSmithKline plc, Zydus Cadila, Bionpharma  2020/10/07 14:57:26 OpenPR
Data Bridge Market Research has added an exhaustive research study of the Shigellosis Gastroenteritis Treatment Market driver and intricately analyzing the business vertical. The research report has abilities to raise as the most significant market worldwide as it has remained
   Live Attenuated Vaccines Market Size and Growth to 2026: Sanofi, Emergent BioSolutions Inc, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, AstraZeneca  2020/10/06 12:05:22 OpenPR
Global live attenuated vaccines market is expected to grow at a growing CAGR in the forecast period of 2019-2026. Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling
   Vaccine Market Professional Survey Report: Merck Co., Inc, Sanofi, CSL Limited, Panacea Biotec Ltd., Novavax, Emergent BioSolutions Inc, Inovio Pharmaceuticals, Inc  2020/09/30 19:15:01 OpenPR
Vaccine Market By Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Others), Type (Monovalent Vaccines, Multivalent Vaccines), Indication (Pneumococcal Disease, Influenza, Meningococcal Disease, Polio, Rotavirus, Hepatitis, Dengue, Herpes Zoster, Others), Route of Administration (Oral, Parenteral), By End Users (Hospitals,
   Here Is Everything We Know About A COVID-19 Vaccine  2020/09/04 09:30:00 Zero Hedge
Here Is Everything We Know About A COVID-19 Vaccine Tyler Durden Fri, 09/04/2020 - 05:30 Under normal conditions, vaccines require as long as ten years of testing before they're approved by regulators, then it takes some more time for drug companies to produce and distribute the product to millions of patients around the world. Until very recently, the notion that the world could quickly develop and mass produce a vaccine for some new infectious disease within a matter of months seemed impossible. Of course, these aren't normal times. After unveiling the adenovirus-vector vaccine developed by the Gameleya Institute, Russian President Putin claimed that the vaccine was tested first on a small group of willing participants, including one of his own adult daughters. The implication was that traditional standards of medical ethics don't always apply during extreme situations. With vaccine news being the dominant story on Thursday , as investors around the world watched as the administration pushed the states to prepare to start distributing vaccine doses on an emergency basis come Nov. 1.
   Uma Sharma, PhD of MMS Holdings and Ron Perry of Emergent BioSolutions Join MichBio Board of Directors  2020/08/18 20:14:00 Business Wire
ANN ARBOR, Mich.--(BUSINESS WIRE)-- #bioindustry--MichBio welcomes Uma Sharma, PhD Chief Scientific Officer at MMS Holdings and Ron Perry Vice President and General Manager at Emergent BioSolutions to the Board of Directors. Uma Sharma, PhD was appointed in mid-August to complete a term expiring in December 2021. As the CSO of MMS Holdings, she is a hands-on leader focused on guiding sponsors on clinical strategy and colleagues through an inclusive leadership model. Dr. Sharma has a personal philosophy of pay

 関連キーワード  (医薬品 米国株 EBS エマ―ジェント・バイオソリュ―ションズ EBS )

 twitter  (公式ツイッターやCEOツイッターなど)